ARCHIVES

Kyprolis Demonstrates Overall Response Following FDA Accelerated Approval

This article is from The Cancer Letter archive.

Vol. 35 No. 8 | August 31, 2012

Download PDF Visit The Full Archive

Related Articles

FDA Advisors Give Dox-SL Conditional Approval; Ok Zoladex

February 24, 1995

Secret Budget Sessions Ended; HEW Out To Lim. Future NCI Funds

April 2, 1976

ACS Probably Will Accept Hammer’s Offer On Matching Funds For Survey

February 3, 1984

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

March 28, 2014

In brief: ring appointed Associate Dean At UCSF; Univ. of Utah Forms Cell Signaling Center

August 1, 1997

Interview: Burzynski Explains Why He Calls Treatment “Non-Toxic”

September 25, 1998